Roche Holding AG (RHHBF)
Company Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally.
The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.
In addition, the company supplies diagnostic instruments and reagents.
It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD).
The company was founded in 1896 and is headquartered in Basel, Switzerland.
| Country | CH |
| IPO Date | Aug 3, 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 103,249 |
| CEO | Dr. Thomas Schinecker |
Contact Details
Address: Konzern Hauptsitz Basel, CH | |
| Website | https://www.roche.com |
Stock Details
| Ticker Symbol | RHHBF |
| Exchange | PNK |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | CH0012032113 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas Schinecker | Group Chief Executive Officer |
| Cristina A. Wilbur | Chief People Officer |
| Dr. Alan Hippe | Chief Financial Officer |
| Barbara Schadler | Head of Group Communications |
| Boris L. Zaitra | Head of Corporate Business Development |
| Claudia Bockstiegel | General Counsel |
| Dr. Bruno Eschli | Head of Investor Relations |
| Dr. Nicolas Dunant | Head of Group Media Relations |
| Dr. Severin Schwan Ph.D. | Executive Chairman |
| Pascale Schmidt | Chief Compliance Officer |